Skip to main content
Signal8

REVELATION BIOSCIENCES, INC. (REVB)

Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Revelation Biosciences, Inc. logo

Revelation Biosciences, Inc.

NASDAQ:REVBHealthcare
AH-3.48%$3.74
Close$3.88+1.57%
Mkt Cap$2.65M
EV-
Float539K
O/S683K
VOL13K sh
$ Vol$50K
RVOL0.59×
Inst Own6.1%
SI2.4%
Net Cash/Sh-
Dilution
Revelation Biosciences, Inc. logoNASDAQ:REVBAH$3.74-3.48%
Upcoming Catalysts
  • GeminiREADOUT
    Cash runway at this date: -5mo
    Late 2027~58wPR
Pipeline1 lead-sponsored trial·0 active1 completed

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
  • Phase 1/2
    Completed

    Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease.

    Intravenous Gemini, Intravenous placebo

    Renal Insufficiency, Chronic, Chronic Kidney Disease stage3 +1

    Enrollment
    40
    Start
    Jan 2025
    Primary Completion
    Jul 2025
    Completion
    Jul 2025
    NCT06863467